Evidence map›Paper›PMID 40647524›Full record

ArticleCancers2025

Modeling the t(2;5) Translocation of Anaplastic Large Cell Lymphoma Using CRISPR-Mediated Chromosomal Engineering.

Robin Khan, Laurent Phely, Sophia Ehrenfeld, Tatjana Schmitz, Pia Veratti, Jakob Wolfes, Khalid Shoumariyeh, Geoffroy Andrieux, Uta S Martens, Stephan de Bra and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Robin KhanDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Laurent PhelyDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Sophia EhrenfeldDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Tatjana SchmitzDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Pia VerattiDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Jakob WolfesDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Khalid ShoumariyehDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0001-7969-1972
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0002-5389-9481
Uta S MartensDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.ORCID 0009-0002-0549-4807
Stephan de BraDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Martina AuerInstitute of Human Genetics, Medical University of Graz, 8036 Graz, Austria.
Oliver SchillingInstitute of Surgical Pathology, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Melanie BoerriesGerman Cancer Consortium (DKTK), Partner Site Freiburg, 79106 Freiburg, Germany.
Michael SpeicherInstitute of Human Genetics, Medical University of Graz, 8036 Graz, Austria.
Anna L IllertDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Justus DuysterDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0001-7325-7753
Cornelius MiethingDepartment of Medicine I, University Medical Center Freiburg, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0003-4699-3805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesALK+ Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma that is characterized by expression of the Anaplastic Lymphoma Kinase (ALK), which is induced by the t(2;5) chromosomal rearrangement, leading to the expression of the NPM-ALK fusion oncogene. Most previous preclinical models of ALK+ ALCL were based on overexpression of the

methodsTo improve the existing ALCL models and more closely recapitulate the oncogenic events in ALK+ ALCL, we employed CRISPR/Cas-based chromosomal engineering to selectively introduce translocations between the

resultsBy inducing precise DNA cleavage at the syntenic loci on chromosome 11 and 17 in a murine IL-3-dependent Ba/F3 reporter cell line, we generated de novo

conclusionsThus, CRISPR-mediated recombination provides a novel and more faithful approach to model oncogenic translocations, which may lead to an improved understanding of the molecular pathogenesis of ALCL and enable more accurate therapeutic models of malignancies driven by oncogenic fusion proteins.

Indexed as

ALCLchromosomal engineeringchromosomal translocationCRISPR/CasNpm-Alkoncogenic fusion protein

Identifiers

PMID40647524
PMCPMC12249153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.